Talk:Kidney tumours: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
→RCC and BRCA2 mutations: new section |
||
| Line 9: | Line 9: | ||
The patient is eligible for genetic testing via Cancer Care Ontario's Hereditary Cancer Testing program, as they are less than age 45 years at the time of the diagnosis. | The patient is eligible for genetic testing via Cancer Care Ontario's Hereditary Cancer Testing program, as they are less than age 45 years at the time of the diagnosis. | ||
https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/HCTEligibilityCriteriaV3_0.pdf | https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/HCTEligibilityCriteriaV3_0.pdf | ||
== RCC and BRCA2 mutations == | |||
https://pubmed.ncbi.nlm.nih.gov/39673614/ CK7+ CK20+ CAIX+ | |||
Latest revision as of 22:22, 4 February 2025
Kidney biopsy - RCC
Final
Kidney, right renal mass, core biopsy: - Renal cell carcinoma, conventional (clear cell) type. - Fuhrman grade 2 (in the sampled tumour).
Genetic testing - young patient
The patient is eligible for genetic testing via Cancer Care Ontario's Hereditary Cancer Testing program, as they are less than age 45 years at the time of the diagnosis. https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/HCTEligibilityCriteriaV3_0.pdf
RCC and BRCA2 mutations
https://pubmed.ncbi.nlm.nih.gov/39673614/ CK7+ CK20+ CAIX+